Status:
COMPLETED
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment
Eligibility Criteria
Inclusion
- CGI - S ≥4
- PANSS ≥ 80
- Inpatients or outpatients
Exclusion
- Patients with a history of myeloproliferative diseases, history of granulocytopenia, agranulocytosis due to a drug
- Diagnosis of substance dependence within previous 3 months using DSM-IV criteria
- History of seizure
- Organic mental disease, including mental retardation or epilepsy
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2004
Estimated Enrollment :
147 Patients enrolled
Trial Details
Trial ID
NCT00649844
Start Date
January 1 2003
End Date
September 1 2004
Last Update
February 21 2021
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Città di Castello, Perugia, Italy, 06012
2
Pfizer Investigational Site
Bassano del Grappa, Vicenza, Italy, 36061
3
Pfizer Investigational Site
Bari, Italy, 70124
4
Pfizer Investigational Site
Brescia, Italy, 25100